Dengue is a mosquito-transmitted virus and the leading cause of arthropod-borne viral disease in the world. It is also known as breakbone fever due to the severity of muscle spasms and joint pain, dandy fever, or seven-day fever because of the usual duration of symptoms. Although most cases are asymptomatic, severe illness and death may occur. Aedes mosquitoes transmit the virus and are common in tropical and subtropical parts of the world. The incidence of dengue has increased dramatically over the past few decades. The infection is now endemic in some parts of the world. A few people who were previously infected with one subspecies of the dengue virus develop severe capillary permeability and bleeding after being infected with another subspecies of the virus. This illness is known as dengue hemorrhagic fever.
It is the fastest spreading mosquito-borne viral disease in the world, affecting greater than 100 million humans annually. Dengue also causes 20 to 25,000 deaths, primarily in children, and is found in more than 100 countries. Epidemics occur annually in the Americas, Asia, Africa, and Australia. Two transmission cycles maintain the dengue virus: 1) mosquitos carry the virus from a non-human primate to a non-human primate and 2) mosquitos carry the virus from human to human. The human-mosquito cycle occurs primarily in urban environments. Whether the virus transmits from human to mosquito is dependent upon the viral load of the mosquito’s blood meal.
The primary vectors of the disease are female mosquitoes of the species Aedes aegypti and Aedes albopictus. Although A. aegypti is associated with most infections, A. albopictus’ range is expanding and may be associated with increasing numbers. These species of mosquitoes tend to live indoors and are active during the day. Transmission perinatally, via blood transfusions, breast milk, and by organ transplantation have been reported.
After 2010, the mean age of patients was 34 years as compared to 27.2 years from 1990 to 2010. The dengue viral serotype causing disease outbreaks has varied with time, as has the occurrence of severe dengue fever.
Part of the Flavivirus family, the dengue virus is a 50 nm virion with three structural and seven nonstructural proteins, a lipid envelope, and a 10.7 kb capped positive sense single strand of ribonucleic acid. Infections are asymptomatic in up to 75% of infected humans. A spectrum of disease, from self-limiting dengue fever to hemorrhage and shock, may be seen. A fraction of infections (0.5% - 5%) progress to severe dengue. Without proper treatment, fatality rates may exceed 20%. These occur primarily in children. The typical incubation period for the disease is 4 to 7 days, but it can last from 3 to 10 days. Symptoms more than two weeks after exposure are unlikely to be due to dengue fever.
The exact course of events following the dermal injection of dengue virus by a mosquito bite is unclear. Skin macrophages and dendritic cells appear to be the first targets. It is thought that the infected cells then move to the lymph nodes and spread through the lymphatic system to other organs. Viremia may be present for 24 to 48 hours before the onset of symptoms. A complex interaction of host and viral factors then occurs and determines whether the infection will be asymptomatic, typical, or severe. Severe dengue fever with increased microvascular permeability and shock syndrome is thought to be associated with infection due to a second dengue virus serotype and the patient's immune response. However, cases of severe dengue do occur in the setting of infection by only a single serotype. Worsening microvascular permeability often transpires even as viral titers fall.
The three phases of dengue include febrile, critical, and recovery.
During the febrile phase, a sudden high-grade fever of approximately 40 C occurs that usually lasts two to seven days. Associated symptoms include facial flushing, skin erythema, myalgias, arthralgias, headache, sore throat, conjunctival injection, anorexia, nausea, and vomiting. For skin erythema, a general blanchable macular rash occurs in the first one to two days of fever and the last day of fever. Or, within 24 hours, a secondary maculopapular rash can develop.
Defervescence characterizes the critical phase with a temperature of approximately 37.5 C to 38 C or less on days three through seven. It is associated with increased capillary permeability. This phase usually lasts one to two days. It can progress to shock, organ dysfunction, disseminated intravascular coagulation, or hemorrhage.
The recovery phase entails the gradual reabsorption of extravascular fluid in two to three days. The patient will display bradycardia at this time.
Criteria for Dengue Include:
The virus antigen can be detected by ELISA, polymerase chain reaction, or isolation of the virus from body fluids. Serology will reveal a marked increase in immunoglobulins.
It is vital to assess pregnant patients with dengue as the symptoms may be very similar to preeclampsia.
Supportive management includes giving the patient fluids, acetaminophen for fever, and a blood transfusion for hemorrhage. Confirmed diagnosis is established by culture, antigen detection, polymerase chain reaction, or serologic testing. Avoid giving aspirin and nonsteroidal anti-inflammatory drugs and other anticoagulants. No antiviral medications are recommended.
Patients with thrombocytopenia or bleeding may require platelets and fresh frozen plasma.
No laboratory tests can predict the progression to severe disease.
The clinical diagnosis of dengue can be challenging as many other illnesses can present similarly early in the disease course. Other considerations should include malaria, influenza, Zika, chikungunya, measles, and yellow fever. Obtain a detailed history of immunizations, travel, and exposures.
Rapid laboratory identification of dengue fever includes NS1 antigen detection and serologic tests. Serologic tests are only useful after several days of infection and may be associated with false positives due to other flavivirus infections, such as yellow fever or Zika virus.
Untreated severe dengue fever may have a mortality rate of 10% to 20%. Appropriate supportive care reduces the mortality rate to roughly 1%.
Patients should be encouraged to consume ample liquids. The return of a patient's appetite is a sign that the infection is subsiding.
Consulting an infectious disease specialist is recommended because most clinicians have little experience managing this infection. The Centers for Disease Control and Prevention has a hotline which also offers advice on treatment.
The only way to avoid contracting dengue is to prevent mosquito bites and not travel to its endemic areas.
Other preventative measures include the use of DEET insecticide, wearing protective clothing, sleeping under a mosquito net, and eliminating stagnant water around the home.
The diagnosis and management of dengue is complex and this best managed by an interprofessional team that includes an infectious disease expert, CDC consultant, emergency department physician and an internist. The care is supportive with fluid, acetaminophen for fever, and a blood transfusion for hemorrhage. Confirmed diagnosis is established by culture, antigen detection, polymerase chain reaction, or serologic testing. No laboratory tests can predict the progression to severe disease.
The role of the primary care provider and nurse practitioner is to educate the traveler on the prevention of mosquito bites. This means covering exposed skin, and use bed nets, particularly during daytime siestas, using mosquito repellents and indoor insecticides. One should also eradicate mosquito breeding grounds like standing water. The prognosis for untreated dengue is abysmal but with supportive care, most patients can survive, albeit with residual multisystem organ damage.
|||Baak-Baak CM,Cigarroa-Toledo N,Pech-May A,Cruz-Escalona GA,Cetina-Trejo RC,Tzuc-Dzul JC,Talavera-Aguilar LG,Flores-Ruiz S,Machain-Williams C,Torres-Chable OM,Blitvich BJ,Mendez-Galvan J,Garcia-Rejon JE, Entomological and virological surveillance for dengue virus in churches in Merida, Mexico. Revista do Instituto de Medicina Tropical de Sao Paulo. 2019 Feb 14; [PubMed PMID: 30785563]|
|||Sharma M,Glasner DR,Watkins H,Puerta-Guardo H,Kassa Y,Egan MA,Dean H,Harris E, Magnitude and Functionality of the NS1-Specific Antibody Response Elicited by a Live-Attenuated Tetravalent Dengue Vaccine Candidate. The Journal of infectious diseases. 2019 Feb 19; [PubMed PMID: 30783676]|
|||Oliveira LNDS,Itria A,Lima EC, Cost of illness and program of dengue: A systematic review. PloS one. 2019; [PubMed PMID: 30785894]|
|||Seixas G,Salgueiro P,Bronzato-Badial A,Gonçalves Y,Reyes-Lugo M,Gordicho V,Ribolla P,Viveiros B,Silva AC,Pinto J,Sousa CA, Origin and expansion of the mosquito Aedes aegypti in Madeira Island (Portugal). Scientific reports. 2019 Feb 19; [PubMed PMID: 30783149]|
|||Ghani NA,Shohaimi S,Hee AK,Chee HY,Emmanuel O,Alaba Ajibola LS, Comparison of Knowledge, Attitude, and Practice among Communities Living in Hotspot and Non-Hotspot Areas of Dengue in Selangor, Malaysia. Tropical medicine and infectious disease. 2019 Feb 15; [PubMed PMID: 30781369]|
|||Maia LMS,Bezerra MCF,Costa MCS,Souza EM,Oliveira MEB,Ribeiro ALM,Miyazaki RD,Slhessarenko RD, Natural vertical infection by dengue virus serotype 4, Zika virus and Mayaro virus in Aedes (Stegomyia) aegypti and Aedes (Stegomyia) albopictus. Medical and veterinary entomology. 2019 Feb 18; [PubMed PMID: 30776139]|
|||Prompetchara E,Ketloy C,Thomas SJ,Ruxrungtham K, Dengue vaccine: Global development update. Asian Pacific journal of allergy and immunology. 2019 Jan 13; [PubMed PMID: 30660171]|
|||Vasanthapuram R,Shahul Hameed SK,Desai A,Mani RS,Reddy V,Velayudhan A,Yadav R,Jain A,Saikia L,Borthakur AK,Mohan DG,Bandyopadhyay B,Bhattacharya N,Dhariwal AC,Sen PK,Venkatesh S,Prasad J,Laserson K,Srikantiah P, Dengue virus is an under-recognised causative agent of acute encephalitis syndrome (AES): Results from a four year AES surveillance study of Japanese encephalitis in selected states of India. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2019 Jan 11; [PubMed PMID: 30641206]|
|||Thang NT,Probandari A,Ahmad RA, Barriers to Engaging Communities in a Dengue Vector Control Program: An Implementation Research in an Urban Area in Hanoi City, Vietnam. The American journal of tropical medicine and hygiene. 2019 Jan 14; [PubMed PMID: 30652660]|
|||Wharton-Smith A,Green J,Loh EC,Gorrie A,Omar SFS,Bacchus L,Lum LCS, Using clinical practice guidelines to manage dengue: a qualitative study in a Malaysian hospital. BMC infectious diseases. 2019 Jan 11; [PubMed PMID: 30634929]|
|||Kellstein D,Fernandes L, Symptomatic treatment of dengue: Should the NSAID contraindication be reconsidered? Postgraduate medicine. 2018 Dec 21; [PubMed PMID: 30575425]|
|||Nujum ZT,Saritha N,Prathibha Raj MR,Gayathri AV,Nirmala C,Vijayakumar K,Varghese S, Seroprevalence of dengue infection in pregnant women and placental antibody transfer. Medical journal, Armed Forces India. 2019 Jan; [PubMed PMID: 30705485]|
|||Gordon A,Gresh L,Ojeda S,Katzelnick LC,Sanchez N,Mercado JC,Chowell G,Lopez B,Elizondo D,Coloma J,Burger-Calderon R,Kuan G,Balmaseda A,Harris E, Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua. PLoS medicine. 2019 Jan; [PubMed PMID: 30668565]|